Artisan Partners Limited Partnership Acquires 107,292 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Artisan Partners Limited Partnership increased its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 27.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 499,134 shares of the biopharmaceutical company's stock after acquiring an additional 107,292 shares during the period. Artisan Partners Limited Partnership owned about 0.88% of Agios Pharmaceuticals worth $16,402,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Erste Asset Management GmbH bought a new position in Agios Pharmaceuticals during the 3rd quarter valued at about $97,199,000. Vestal Point Capital LP bought a new position in shares of Agios Pharmaceuticals in the third quarter valued at approximately $33,767,000. State Street Corp boosted its holdings in shares of Agios Pharmaceuticals by 10.2% in the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock worth $103,586,000 after acquiring an additional 216,484 shares in the last quarter. Frazier Life Sciences Management L.P. grew its position in Agios Pharmaceuticals by 19.7% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company's stock worth $46,392,000 after acquiring an additional 172,180 shares during the last quarter. Finally, Fisher Asset Management LLC increased its holdings in Agios Pharmaceuticals by 12.3% during the 4th quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock valued at $31,567,000 after purchasing an additional 105,333 shares in the last quarter.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now directly owns 18,906 shares of the company's stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.93% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Royal Bank of Canada increased their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a report on Tuesday, December 10th. Scotiabank increased their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, December 9th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 price target for the company. StockNews.com downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of "Hold" and an average target price of $56.57.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO traded up $0.84 on Wednesday, reaching $28.24. The stock had a trading volume of 311,218 shares, compared to its average volume of 717,866. Agios Pharmaceuticals, Inc. has a 1-year low of $26.66 and a 1-year high of $62.58. The firm has a fifty day moving average of $32.99 and a two-hundred day moving average of $40.58. The company has a market cap of $1.62 billion, a P/E ratio of 2.49 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.